ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0576

Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers

Andrew Concoff1, Vasileios Kyttaris2, Vaneet Sandhu3, Tyler O'Malley4, Giorgio Casaburi4, Sudha Kumar4, Chau Ching Liu5, Susan Manzi6 and Joeseph Ahearn5, 1Exagen, Los Angeles, CA, 2BIDMC, Boston, MA, 3Loma Linda University, Loma Linda, CA, 4Exagen, Vista, CA, 5Allegheny Health Network, Pittsburgh, PA, 6Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Biomarkers, Cohort Study, complement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease, affecting multiple organ systems with varying severity among patients. SLE presents a diagnostic challenge due to its protean clinical manifestations. Current standard of care biomarkers such as anti-dsDNA, anti-Smith, and complement proteins C3/C4 have limited discriminatory power characterized by poor sensitivity in incipient cases of SLE. This study aims to compare the clinimetric performance of T-cell bound complement split product C4d (TC4d) and anti-T-cell antibodies IgG (TIgG) and IgM (TIgM) with conventional biomarkers in differentiating Systemic Lupus Erythematosus (SLE) from clinically relevant controls (CRCs).

Methods: A total of 230 patients were included in the analysis (SLE = 80; CRC = 150) (Table 1). SLE patients were required to meet either the 1997 ACR, 2012 SLICC, or 2019 ACR/EULAR classification criteria for SLE; CRCs were required to have a clinical diagnosis with an associated ICD-9/ICD-10 code to confirm clinical diagnosis as enumerated in the Table 1 caption. A comprehensive machine learning pipeline integrating feature selection, multiple model architectures training, and cross-validation (CV) techniques was employed to compare the relative diagnostic performances of TIgG, TIgM, and TC4d to conventional SLE biomarkers. The robustness and generalizability of the pipeline were validated through permutational hold-out (HO) predictions, mitigating the risk of overfitting the models developed.

Results: The SLE cohort had a higher proportion of females (96.3% vs. 77.3%), younger age (mean [SD]: 47.1 [13.9] vs. 53.6 [14.3] years), and fewer Caucasians (65.0% vs. 82.7%) as compared to the CRC group (Table 1). Cumulative ROC analysis derived from multiple 10-fold CV models showed the diagnostic performances of TC4d (AUC = 0.86), TIgG (AUC = 0.81), and TIgM (AUC = 0.78) outperformed C3 (AUC = 0.77), anti-dsDNA (AUC = 0.76), anti-Smith (AUC = 0.72), and C4 (AUC = 0.70) (Figure 1, A). While the specificity of TIgG, TIgM, TC4d compared to conventional biomarkers were similar in CV models, the sensitivity for SLE in both 10-CV and HO partitions were significantly higher for TIgG, TIgM, and TC4d compared to conventional biomarkers (Figure 1 B, C). Comparing median blood levels of TC4d and TIgG confirmed a statistically significant difference between SLE and CRC (P< 0.0001) (Figure 2), further highlighting their intrinsic discriminatory power.

Conclusion: The study demonstrates the potential of TIgG, TIgM, and TC4d as sensitive and specific biomarkers for the diagnosis of SLE with improved diagnostic performance relative to conventional biomarkers. These findings suggest an opportunity for improved diagnostic accuracy that could yield timely treatment initiation and improved patient outcomes in SLE. However, further studies are needed to validate the results among larger, more diverse patient cohorts and to determine how T cell antibodies and TC4d biomarkers may improve upon existing integrated diagnostic biomarker solutions. Future efforts will explore the potential of T-Cell biomarkers to predict disease progression and as surrogates of treatment response.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Concoff: Exagen, 3, 4, 12, Shareholder, Pacira Biosciences, Inc., 2, United Rheumatology, 4; V. Kyttaris: AbbVie/Abbott, 5, AstraZeneca, 2, Aurinia, 1, EMD Serono, 5, Exagen, 2, 5, Fresenius Kabi, 1, Horizon Pharmaceuticals, 1, Novartis, 5, Scipher, 1, Takeda, 5, Vertex, 2; V. Sandhu: Exagen, 2, 5; T. O'Malley: Exagen, 3, 11, 12, Shareholder; G. Casaburi: Exagen Inc., 3; S. Kumar: Exagen, Inc., 3; C. Liu: Exagen Diagnostics, 9, 10; S. Manzi: AbbVie, 5, Allegheny Singer Research Institute, 10, AstraZeneca, 2, 5, Exagen Diagnostics, Inc, 2, 9, 10, GSK, 2, 5, Lilly, 2, Lupus Foundation of America, 4, Novartis, 2, UCB Advisory Board, 2, Univiersity of Pittsburgh, 10; J. Ahearn: Exagen Inc, 5, 6, 10.

To cite this abstract in AMA style:

Concoff A, Kyttaris V, Sandhu V, O'Malley T, Casaburi G, Kumar S, Liu C, Manzi S, Ahearn J. Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/enhancing-systemic-lupus-erythematosus-diagnosis-comparative-performance-characteristics-of-tc4d-and-anti-t-cell-antibodies-with-conventional-biomarkers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhancing-systemic-lupus-erythematosus-diagnosis-comparative-performance-characteristics-of-tc4d-and-anti-t-cell-antibodies-with-conventional-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology